Yu-Ih Hou – Mayor, New Taipei City, Taiwan
Yu-Ih Hou, mayor of New Taipei City, introduces the city and highlights its key competitive advantages and strategic direction of growth as Taiwan’s top economic and cultural destination. Over…
Address: 11F, 80 Linshen North Road, Taipei,Taiwan
Tel: (02)2655-8168
Web: http://www.ibmi.org.tw/client/
The Institute for Biotechnology and Medicine Industry (IBMI) is a non-profit organization registered with the relevant authorities of Taiwan. Supported by the President of Legislative Yuan, Mr. Wang Jin-Pyng, the predecessor of IBMI began its operation in 1998. In 1999, Mr. Wang took on the post as the chairman and defined the mission of IBMI as ‘Upgrading Biotechnology and Medicine for National Health’. In March 2002, IBMI was officially founded as an organization dedicated to promoting the biotechnology and medicine industry. In June 2005, IBMI convened its first member conference of the second year where the second board of directors and supervisors were elected. The board continued to uphold the ideology and mission of the organization to push forward industrial growth. In May 2009, at the first member conference of the third year the third board of directors and supervisors were elected. Mr. Wang Jin-Pyng was unanimously honored as the founder of IBMI and for his contribution to the biotechnology and medicine industry. Former President of National Taiwan University and the Vice Chairman of IBMI, Dr. Chen Wei-Zhao was elected as chairman of the third board of directors and supervisors to lead IBMI.
The mission of IBMI is to best utilize the collective public and private resources for successfully developing Taiwan’s biomedical industry, specifically, to establish platforms for biomedical industrial cooperation and resource sharing in order to achieve goals concerning biomedical technology and its commercialization, healthcare and healthcare service, and social welfare.
From perspective of policy development, at IBMI, it is considered that productive industry policy and market mechanism are essential for assuring the best interest of the state and the public. Innovation-based approaches to developing the emerging industry and market-oriented approaches to commercialization are keys to improving state’s economic competitiveness. Therefore, IBMI intends to assist government and industry in formulating and implementing relevant industrial policies, establishing market mechanism, fostering innovation, and ensuring global competitiveness.
Based on the above considerations, IBMI sets its priority to cause productive partnerships among academia, government, industry and research institutions. Therefore, through promotion and operation of its six functions, i.e., ‘Productive Legislation and Policies’, ‘Certification and Market Mechanism’, ‘Education and Training’, ‘Bioinformatics and Bio-trading’, ‘Advanced and Applied Bio-researches’, and ‘Emerging Business Development’, IBMI strives to develop Taiwan’s biomedical industry, improve the quality of its healthcare system, as well as enhance its overall competitiveness.
The Institute for Biotechnology and Medicine Industry (IBMI) is a non-profit organization registered with the relevant authorities of Taiwan.The mission of IBMI is to best utilize the collective public and private resources for successfully developing Taiwan’s biomedical industry, specifically, to establish platforms for biomedical industrial cooperation and resource sharing in order to achieve goals concerning biomedical technology and its commercialization, healthcare and healthcare service, and social welfare.
Yu-Ih Hou, mayor of New Taipei City, introduces the city and highlights its key competitive advantages and strategic direction of growth as Taiwan’s top economic and cultural destination. Over…
Wei-Hong Tseng, founder and chairman of PharmaCore Biotech, introduces the specialized CDMO and its unique capacities to produce high value-added products. As a leading service provider in Taiwan, Tseng goes…
Carol Cheng, chief operating officer of the Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA), gives an update on the current condition of Taiwan’s biopharma environment and speaks about the country’s innovative…
Bach Chen, CEO of Maisense, highlights the innovative new solutions that the company has created in cardiovascular preventative medicine. Their advanced technology, Freescan, is providing an advanced solution to prevent…
Alan Tsai, general manager, and Carson Chen, chief technology officer of iXensor introduce the startup as an innovative player in the point-of-care diagnostics and digital health space. They jointly discuss…
Dr Jan-Mou Lee, founder of FullHope Biomedical, shares his story of how he came to establish his company after a realization about the loss of impact that occurs when critical…
Arthur Kadurin, CEO of Insilico Medicine Taiwan, tells us how artificial intelligence can change drug discovery process using the innovative generative adversarial networks (GANs) approach. AI is the future…
Ed Deng, co-founder and CEO of Health2Sync, a digital health startup specialized in diabetes management, shares how the application is revolutionizing the ability of patients to take control of the…
Tsung-Tsong Wu, minister without portfolio, offers insights into the current state of Taiwan’s biomedical landscape three years after the administration’s Biomedical Industry Innovation Program was put into place to bolster…
Dr Tse Wen Chang, founder of Immunwork, gives an update on the preclinical development process of the company’s revolutionary T-E pharmaceutical products and goes on to give his expert insights…
Dr James Chih-Hsin Yang, director of National Taiwan University Hospital’s department of oncology, speaks about oncology in Taiwan and the role that the NTU network plays in the island’s oncology…
Rongjin Lin, chairman of Center Ventures and Center Laboratories shares his story of how he revived Center Laboratories from the brink of bankruptcy and repositioned the pharmaceutical company to become…
See our Cookie Privacy Policy Here